Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
Date:10/18/2011

SEATTLE, Oct. 19, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management will present at the 10th Annual BIO Investor Forum on Tuesday, October 25th at 11:30 a.m. Pacific/ 2:30 p.m. Eastern/ 8:30 p.m. Central European time in the Presidio Room of the Palace Hotel in San Francisco.

The presentation will also be webcast live with slides, and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.

BIO Investor Forum
CTI Presentation: Tuesday, October 25th, 2011
11:30 a.m. Pacific/ 2:30 p.m. Eastern/ 8:30 p.m. Central European
Presidio Room, Palace Hotel
Audio webcast with slides at www.celltherapeutics.com Media Contact:Investors Contact:Cell Therapeutics, Inc.Cell Therapeutics, Inc.Dan Eramian

Ed BellT: 206.272.4343

T: 206.272.4345F: 206.272.4434

Lindsey Jesch LoganE: media@ctiseattle.com

T: 206.272.4347www.celltherapeutics.com/press_room

F: 206.272.4434E: invest@ctiseattle.comwww.celltherapeutics.com/investors
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , February 11, 2016 --> ... of a new research report, titled "Sports Medicine Devices Market ... 2013 - 2019". According to the report, the global sports ... CAGR from 2013 to 2019, growing from a value of ... --> --> The global sports ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... F ast access ... at the point of need ... medical information products and services, has launched a ClinicalKey mobile ... a mobile device. Elsevier designed the mobile app to allow users to ... available in Android and iOS formats for mobile ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, as ... The puck drops at 6:00pm, but fans will have the opportunity to experience the ... The MEGA Heart will be located on Ford Thunder Alley and provide fans with ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 ... but would shift more of the cost burden to military beneficiaries. , MOAA’s ... in the defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... discuss how to improve care by making data on heart procedures public and ... Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):